Arthrofibrosis After Knee Replacement: Causes & Treatment

Arthrofibrosis after knee replacement is an excessive buildup of scar tissue inside and around the joint that restricts movement, sometimes severely. It affects a meaningful minority of people who undergo total knee arthroplasty (TKA) and ranks among the leading causes of hospital readmission and TKA failure.¹ The condition is driven by the same runaway wound-healing process seen in other fibrotic diseases, but what makes it frustrating for patients is how unpredictable it can be and how much the outcome depends on catching it early.

What Actually Happens Inside the Knee

At its core, arthrofibrosis is a healing response that overshoots. After any surgery, the body lays down collagen to repair damaged tissue. In arthrofibrosis, that process does not shut off on schedule. A signaling molecule called TGF-beta 1 drives certain cells in the joint lining to transform into myofibroblasts, which are essentially collagen-producing machines. The result is dense, stiff scar tissue that fills the joint space and tethers the structures that normally glide smoothly when you bend or straighten your knee.² Researchers have identified thousands of genes whose activity differs between people who develop arthrofibrosis and those who do not, spanning everything from matrix metalloproteinases (enzymes that normally break down scar tissue) to inflammatory cytokines that amplify the fibrotic cascade.³

One promising lead is a receptor called TGFBR1, which sits upstream in that TGF-beta signaling chain. In both animal models and human patients, TGFBR1 levels were significantly higher in arthrofibrotic tissue, and the receptor’s expression correlated strongly with pain scores and range-of-motion loss.⁴ That kind of biomarker could eventually help surgeons identify high-risk patients before the scar tissue has a chance to lock up the joint, though that is still closer to research than routine clinical practice.

Who Is Most at Risk

If you had poor range of motion going into surgery, that is the single strongest predictor of stiffness afterward. People who could barely bend the knee before their replacement tend to have a harder time regaining motion, partly because the joint’s soft tissues are already scarred or contracted.⁵ Diabetes is another well-documented risk factor, as are inflammatory conditions like juvenile rheumatoid arthritis and ankylosing spondylitis. Reflex sympathetic dystrophy (now usually called complex regional pain syndrome) also shows up consistently in the literature as a contributor.⁵

On the surgical side, technical factors can set the stage for stiffness independently of the patient’s biology. If the implant components are the wrong size, if the joint line is positioned too high or too low, if the surgeon removes too little bone, or if the knee ends up malaligned, the mechanical environment of the new joint can provoke chronic stiffness that no amount of physical therapy will fully overcome.⁶ Biomechanical modeling confirms that the position of the tibial insert relative to the joint line and the coronal-plane alignment are among the most influential surgical variables in how a replacement knee performs during everyday activities.⁷

This is an important distinction because treatment differs depending on the cause. If scar tissue is the primary problem, the approach centers on breaking up or removing that tissue. If the implant itself is mechanically wrong, no amount of scar-tissue work will restore motion, and revision surgery to correct the positioning or sizing becomes necessary.⁶

How Arthrofibrosis Is Diagnosed

There is no single blood test or imaging scan that definitively says “arthrofibrosis.” Diagnosis is primarily clinical: persistent range-of-motion limitation, typically defined as flexion below 90 degrees or an extension deficit greater than 5 degrees, lasting more than 12 weeks after surgery and not explained by infection or a mechanical problem with the implant.⁸ The diagnostic challenge lies in ruling out the mimics. Infection, a loose or mispositioned component, or a retained bone fragment can all produce stiffness that looks and feels similar. Blood work, joint aspiration, and imaging are used mainly to exclude those other causes before settling on a fibrosis diagnosis.

Advanced MRI with metal artifact reduction techniques can visualize fibrosis within the joint, and an MRI-based classification of how thickened the synovial tissue appears has been shown to correlate with the severity of range-of-motion deficits. Still, MRI remains more of a supplemental tool than a definitive diagnostic test, and many surgeons rely on the clinical picture, the patient’s history, and radiographs showing well-positioned components before concluding that fibrosis is the culprit.

Non-Surgical Treatment

The first line of treatment is always physical therapy, and in most cases, early and aggressive rehab is enough to prevent arthrofibrosis from taking hold. When standard therapy plateaus, though, static progressive stretch (SPS) devices have emerged as a well-supported option. These are adjustable braces that hold the knee at its end range for sustained periods, gradually lengthening the shortened tissues without the high-force bursts of traditional stretching. A large body of evidence supports the approach: one review summarized over 50 published studies showing roughly 90% improvement in range of motion, an 84% reduction in stiffness and swelling, and a 70% reduction in pain, with no reports of complications or injury.⁹

In one study focused specifically on patients whose arthrofibrosis had not responded to conventional therapy, SPS use over a median of seven weeks produced a median gain of 25 degrees in total range of motion. Over 90% of those patients were satisfied with the result.¹⁰ For many people, SPS devices provide enough improvement to avoid a return to the operating room, making them a practical bridge between standard rehab and more invasive procedures.

Continuous passive motion (CPM) machines, which slowly cycle the knee through a set arc while you lie in bed, were once standard after knee replacement. But a meta-analysis comparing CPM to physical therapy alone found no meaningful difference in long-term range of motion for either flexion or extension. CPM also led to longer hospital stays and higher treatment costs.¹¹ Most surgeons have moved away from routine CPM use, though some still prescribe it selectively.

Medications That May Help Prevent or Reduce Stiffness

An intriguing line of evidence suggests that certain common medications can reduce the risk of developing stiffness in the first place. In a study of more than 100,000 knee replacement patients, those who used specific anti-fibrotic medications around the time of surgery had lower rates of needing a subsequent manipulation under anesthesia. The blood-pressure drug losartan stood out, associated with a roughly 20% lower likelihood of requiring manipulation. COX-2 inhibitors (a class of anti-inflammatory drugs) showed a similar effect, as did ACE inhibitors more broadly.¹²

Separately, perioperative use of NSAIDs was linked to about a one-third reduction in the odds of developing arthrofibrosis, while oral corticosteroids showed an even larger association with reduced risk of needing manipulation.¹³ These are observational findings rather than randomized trial results, so they do not prove causation. But the consistency across large datasets and the biological plausibility (all of these drugs dampen inflammatory pathways involved in fibrosis) make them worth discussing with your surgeon, especially if you are already taking one of these medications for blood pressure or inflammation.

Manipulation Under Anesthesia

When physical therapy and bracing have not restored adequate motion, manipulation under anesthesia (MUA) is the most common next step. The procedure is straightforward: while you are under general or spinal anesthesia, the surgeon forcefully bends and straightens the knee to break up adhesions. It sounds aggressive, and it is, but the scar tissue in the early postoperative period is still relatively immature and can be disrupted mechanically. Timing matters enormously. A multicenter randomized trial found that MUA performed between 4 and 12 weeks after surgery produced an immediate average gain of 46 degrees, improving range of motion from about 72 degrees to 118 degrees. At one year, patients maintained an average gain of 37 degrees.¹⁴

Earlier work reinforced the importance of timing: patients who underwent manipulation within 12 weeks had a mean flexion gain of about 37 degrees and a final range of motion of 119 degrees, compared with only 17 degrees of gain and a final range of 95 degrees for those manipulated after 12 weeks. Beyond 26 weeks, manipulation results were generally unsatisfactory.¹⁵ The practical takeaway: if your range of motion is stalling in the first couple of months after surgery, do not wait and hope. Prompt MUA within that 12-week window offers substantially better results.

Arthroscopic Lysis of Adhesions

For patients who do not respond to MUA, or whose stiffness has become more established, arthroscopic lysis of adhesions (LOA) is the next tier. The surgeon inserts a small camera and instruments into the joint and physically cuts or removes the bands of scar tissue. A systematic review of this approach found a mean improvement of about 42 degrees in the arc of motion, from roughly 81 degrees preoperatively to about 123 degrees afterward.¹⁶ That is a significant functional gain, though about 10 to 14% of patients in the reviewed studies needed the procedure repeated.¹⁶ The recurrence rate underscores an uncomfortable reality: some patients’ biology keeps producing scar tissue no matter how thoroughly it is cleared.

Revision Surgery for Severe or Refractory Cases

When the problem is either an implant that is mechanically contributing to stiffness or scar tissue so severe that less invasive procedures have failed, full revision surgery becomes the conversation. Revision TKA for arthrofibrosis significantly improves range of motion, with studies reporting over 25 degrees of improvement in the total arc of motion at a mean follow-up of about four and a half years. Final range of motion after revision tends to be similar to what the patient had before the original replacement, which for many people represents a meaningful reset.¹⁷

For patients with the most severe stiffness, rotating-hinge implants have shown particularly strong results. These implants have a built-in hinge mechanism that provides inherent stability and allows movement even in a joint surrounded by compromised soft tissue. In a comparison of severe versus non-severe arthrofibrosis, patients who received a rotating-hinge implant gained an average of about 41 degrees of motion, compared with 18 degrees for those who received a non-hinge design.¹⁸ Interestingly, patient-reported functional outcomes were similar between the two groups at final follow-up, suggesting that the functional benefit of a larger range-of-motion gain plateaus at a certain point.

Low-Dose Radiation as a Supplementary Tool

One of the more unusual treatment strategies involves preoperative low-dose radiation therapy, borrowed from the playbook used to prevent heterotopic ossification (abnormal bone growth) in other orthopedic procedures. The idea is to quiet the fibroblast activity before the revision surgery so scar tissue is less likely to reform afterward. A review of 60 patients treated with low-dose radiation before rotating-hinge revision found that at a mean six-year follow-up, 98% had a flexion contracture of 10 degrees or less and 82% achieved at least 90 degrees of flexion. No radiation-related complications were reported. However, the more prior surgeries a patient had, the worse the final range of motion tended to be.¹⁹

A smaller, more recent study of this combined approach reported that patient-reported pain interference scores dropped significantly by three months, and knee function scores nearly doubled from preoperative levels.²⁰ This combination remains a specialized option available at certain centers, not a first-line treatment, but it offers hope for patients with recurrent, seemingly intractable fibrosis who have already been through multiple failed procedures.

The Emotional and Psychological Toll

The medical literature on arthrofibrosis tends to focus on degrees of flexion and surgical techniques, but the lived experience of the condition is considerably more bruising than a range-of-motion number conveys. A qualitative study interviewing people with arthrofibrosis after knee replacement identified an overwhelming impact on social functioning and self-identity, with participants reporting adverse mental health outcomes as their activity levels and independence eroded. Many described significant emotional labor spent trying to understand what was happening to their knee and why their recovery had stalled while others around them seemed to recover smoothly.²¹

A recurring frustration was inconsistency in the advice they received from different healthcare professionals, especially about exercise. Some were told to push harder; others were told to rest. The confusion compounded the distress. For people in this situation, knowing that arthrofibrosis is a recognized medical condition with established treatment options can itself be therapeutic. Too many patients spend months wondering whether they are doing something wrong, when the reality is that their biology mounted an abnormal healing response.

Fear-avoidance behavior can also become self-reinforcing. A case report documented a patient with three years of debilitating knee pain and severe motion restriction after arthroscopic surgery, partly maintained by complex regional pain syndrome. A rehabilitation approach that specifically addressed pain-related fear alongside physical treatment eventually achieved a 110-degree improvement in total knee range of motion and the ability to walk half a mile with minimal pain.²² That is a single case, not a treatment protocol, but it highlights how much psychological factors can contribute to sustained disability when they go unaddressed.

Emerging Biomarkers and the Future of Prediction

A significant frustration in this field is the inability to predict, before or immediately after surgery, who will develop arthrofibrosis. The risk factors mentioned earlier raise or lower the probability, but none of them are precise enough to trigger preemptive action in a specific individual. Researchers are working to change that. RNA sequencing of tissue from patients with arthrofibrosis has revealed thousands of genes with altered expression compared to patients with uncomplicated recoveries, including over 2,000 upregulated and nearly 1,800 downregulated genes in one study comparing arthrofibrotic tissue to normal post-TKA tissue.²³

The challenge is distilling that enormous genetic fingerprint into a practical clinical test. TGFBR1 is the strongest candidate so far, with a receiver operating characteristic area under the curve of 0.838 in one study, meaning it is a reasonably accurate discriminator between patients who develop arthrofibrosis and those who do not.⁴ If a reliable blood or synovial fluid test emerges, the treatment paradigm could shift toward prevention: identify high-risk patients early, deploy aggressive anti-fibrotic medications perioperatively, and monitor range of motion closely in the critical first weeks. That future is still being built, but the molecular groundwork is already in place.